For research use only. Not for therapeutic Use.
IXA6 is a novel IRE1/XBP1s activator, and can induce IRE1 RNase activity[1].
IXA6 (10 µM; 4 or 18 h) selectively activates IRE1-XBP1s signaling, and activates the XBP1s transcriptional response[1].
IXA6 (10 µM; 4 h) shows selectivity for IRE1-XBP1s-dependent ER proteostasis remodeling[1].
IXA6 (10 µM; 18 h) reduces secretion of APP through IRE1 activation[1].
| Catalog Number | I042929 |
| CAS Number | 1021106-40-0 |
| Synonyms | N-[(4-chlorophenyl)methyl]-N-[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]pyridine-3-sulfonamide |
| Molecular Formula | C22H20ClN3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C22H20ClN3O3S/c23-19-9-7-17(8-10-19)15-25(30(28,29)20-5-3-12-24-14-20)16-22(27)26-13-11-18-4-1-2-6-21(18)26/h1-10,12,14H,11,13,15-16H2 |
| InChIKey | INLQYLVXKDCKIT-UHFFFAOYSA-N |
| SMILES | C1CN(C2=CC=CC=C21)C(=O)CN(CC3=CC=C(C=C3)Cl)S(=O)(=O)C4=CN=CC=C4 |
| Reference | [1]. Julia M D Grandjean, et al. Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nat Chem Biol. 2020 Oct;16(10):1052-1061. |
